NasdaqCM - Nasdaq Real Time Price USD

Biomerica, Inc. (BMRA)

3.5000

-0.0600

(-1.69%)

At close: May 14 at 4:00:00 PM EDT

PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

- Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medi

GlobeNewswire 7 days ago

BMRA
-1.69%
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Detection of H. pylori Infection

10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogenThis test empowers healthcare providers with fast, accessible testing across the UAE IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ul

GlobeNewswire 21 days ago

BMRA
-1.69%
Biomerica’s kidney disease test gains approval for sale in UAE

The diagnostic tool delivers outcomes within ten minutes from a urine sample.

Medical Device Network 23 days ago

BMRA
-1.69%
Biomerica Third Quarter 2025 Earnings: US$0.061 loss per share (vs US$0.11 loss in 3Q 2024)

Biomerica ( NASDAQ:BMRA ) Third Quarter 2025 Results Key Financial Results Revenue: US$1.12m (up 10.0% from 3Q 2024...

Simply Wall St. 26 days ago

BMRA
-1.69%
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Disease Test for Early Detection of Kidney Damage

Regulatory milestone enables commercial expansion into high-need international market10-minute test detects early signs of kidney damage using a simple urine sample Addresses global public health burden of Chronic Kidney Disease (CKD), with high relevance in the UAE IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel® Kidney Disease (Microalbumin) Test has been approved for sale by the Un

GlobeNewswire 27 days ago

BMRA
-1.69%
Biomerica Announces Reverse Stock Split

Shares Expected to Begin Trading on Split-Adjusted Basis on April 21, 2025IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, today announced that it will implement a 1-for-8 reverse stock split of the issued and outstanding shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on April 21, 2025. Biomerica’s common stock is expected to begin trading on a split-adjus

GlobeNewswire 28 days ago

BMRA
-1.69%
Biomerica Reports Third Quarter Fiscal 2025 Financial Results

Total Revenue Increases 10% Year-Over-YearDelivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2025 ended February 28, 2025. Key Highlights: 1. Fortel® PSA Screening Test Approved by UAE Ministry of Health &

GlobeNewswire 29 days ago

BMRA
-1.69%
Biomerica’s tests for IBD conditions gain CE-marking under EU’s IVDR

The IVDR certification allows the company to pursue market expansion within Europe's in vitro diagnostic market.

Medical Device Network 2 months ago

BMRA
-1.69%
Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Significant Milestone: Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union standards and allowing sales of the products in the EUFocus on Precision Medicine: Certification covers Biomerica’s food intolerance products developed to support patients with Crohn’s Disease and Ulcerative Colitis (UC), both of which are chronic and debilitating inflammatory bowel diseases (IBD).Global Reach: Positions Biomerica to expand its presence

GlobeNewswire 2 months ago

BMRA
-1.69%
February 2025's Top US Penny Stocks To Consider

As the S&P 500 reaches new heights and the Nasdaq Composite hovers near record levels, investors are closely watching market dynamics that continue to evolve amid mixed trading signals. In this context, penny stocks—often representing smaller or newer companies—remain a compelling area of interest for those seeking potential growth opportunities at lower price points. By focusing on financial strength and solid fundamentals, these stocks can offer upside potential without many of the...

Simply Wall St. 2 months ago

EPIX

SCWO

BMRA
-1.69%
Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal

inFoods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome (IBS)Research Finds Patients Following a Personalized Diet Therapy Created with inFoods® IBS, Experienced Reduced Abdominal Pain and Bloating IRVINE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that patients with Irritable Bowel Syndrome (IBS) may experience significant relief from abdomina

GlobeNewswire 2 months ago

BMRA
-1.69%
January 2025 US Penny Stocks With Promising Potential

As the U.S. stock market experiences a surge, with major indexes like the Dow Jones and S&P 500 on track for significant weekly gains, investors are keenly observing potential opportunities beyond large-cap stocks. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those looking to explore investment possibilities outside mainstream options. Despite being considered an outdated term by some, penny stocks continue to offer unique prospects when they...

Simply Wall St. 3 months ago

FNGR

RFIL

BMRA
-1.69%
Biomerica’s prostate cancer detection test gains approval from MOHAP

Utilising a finger-prick blood sample, the PSA test claims to generate ‘accurate’ outcomes within ten minutes.

Medical Device Network 3 months ago

BMRA
-1.69%
Top Midday Gainers

Biomerica (BMRA) said Thursday that the United Arab Emirates Ministry of Health and Prevention appro

PREMIUM
MT Newswires 3 months ago

BMRA
-1.69%

DOYU
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer - Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel® Prostate Specific Antigen (PSA) Screening Test has received approval from the United Arab Emirates Ministry of Health and Prevention (MOHAP). T

GlobeNewswire 3 months ago

BMRA
-1.69%
Biomerica Second Quarter 2025 Earnings: US$0.055 loss per share (vs US$0.09 loss in 2Q 2024)

Biomerica ( NASDAQ:BMRA ) Second Quarter 2025 Results Key Financial Results Revenue: US$1.64m (up 4.4% from 2Q 2024...

Simply Wall St. 3 months ago

BMRA
-1.69%
Biomerica Reports Second Quarter Fiscal 2025 Financial Results

- Total Revenue Increases 5% Year-Over-Year - Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2025 ended November 30, 2024. Key Highlights: Direct-to-Consumer Launch of inFoods® IBS TestPatients can now order the inFoods®

GlobeNewswire 3 months ago

BMRA
-1.69%
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent Treaty IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedi

GlobeNewswire 5 months ago

BMRA
-1.69%
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements

IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance. This extension was provided because Biomerica currently m

GlobeNewswire 6 months ago

BMRA
-1.69%
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain

Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s officeWith a simple, at-home finger-prick blood sample, patients can receive a personalized test result identifying potential IBS trigger foods The inFoods® IBS test empowers patients with actionable results to reduce bloating and gastrointestinal pain IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a lead

GlobeNewswire 6 months ago

BMRA
-1.69%

Performance Overview

Return	BMRA	S&P 500 (^GSPC)
YTD	+45.83%	+0.19%
1-Year	-27.08%	+12.31%
3-Year	-85.47%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biomerica, Inc. (BMRA)

PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Detection of H. pylori Infection

Biomerica’s kidney disease test gains approval for sale in UAE

Biomerica Third Quarter 2025 Earnings: US$0.061 loss per share (vs US$0.11 loss in 3Q 2024)

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Disease Test for Early Detection of Kidney Damage

Biomerica Announces Reverse Stock Split

Biomerica Reports Third Quarter Fiscal 2025 Financial Results

Biomerica’s tests for IBD conditions gain CE-marking under EU’s IVDR

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

February 2025's Top US Penny Stocks To Consider

Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal

January 2025 US Penny Stocks With Promising Potential

Biomerica’s prostate cancer detection test gains approval from MOHAP

Top Midday Gainers

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

Biomerica Second Quarter 2025 Earnings: US$0.055 loss per share (vs US$0.09 loss in 2Q 2024)

Biomerica Reports Second Quarter Fiscal 2025 Financial Results

Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis

Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements

Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain

Performance Overview